LONDON, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA--(Marketwired - Nov 18, 2013) - GlaxoSmithKline plc (GSK) and Theravance, Inc. (NASDAQ: THRX) announced today that the European Commission has ...
GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a ...
GSK’s new asthma drug Relvar Ellipta has shown itself to be superior to existing treatments in a major real world trial, the Salford Lung Study (SLS). Developed with US respiratory specialist firm ...
The FINANCIAL — GlaxoSmithKline plc on December 2 announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Relvar Ellipta (fluticasone furoate / vilanterol 100/25 mcg) ...
Relvar Ellipta: Over the past few days, research-based pharmaceutical GlaxoSmithKline plc (ADR) (NYSE:GSK) and biopharmaceutical company Theravance Inc (NASDAQ:THRX)’s Relvar Ellipta has been in the ...
GlaxoSmithKline and Innoviva have unveiled data from a second ground-breaking Salford Lung Study (SLS) showing that Relvar Ellipta significantly improved asthma control versus patients’ standard ...
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for fluticasone furoate/vilanterol (FF/VI) (Relvar Ellipta, ...
Trelegy Ellipta is a combination of three molecules in a single inhaler. It contains fluticasone furoate, an inhaled corticosteroid, umeclidinium, a long-acting muscarinic antagonist; and vilanterol, ...
Trelegy Ellipta was approved in the European Union in November 2017 for the treatment of patients with Chronic Obstructive Pulmonary Disease (COPD) who are not adequately treated by an ICS/LABA ...
The European Commission has approved a label update to GlaxoSmithKline/Innoviva’s Relvar Ellipta, expanding the asthma therapy’s reach. The European Commission ...
GSK’s new asthma drug Relvar Ellipta has shown itself to be superior to existing treatments in a major real world trial, the Salford Lung Study (SLS). Developed with US respiratory specialist firm ...
The European Medicine Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended approval of the fixed-dose combination of fluticasone furoate and vilanterol (FF/VI) (Revinty ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results